David Doriguzzi
Medical · Lancaster, CANPI 1730195728
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $106,691 of the $165,568 with a category attached, or 64.4%. 40 manufacturers reported payments, led by Novo Nordisk at 44.8% of the total. 2025 is the largest year on record at $53,472, 2.6 times the $20,446 reported in 2021. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 777 payments — averaging $213.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$74K
- Dexcom, Inc.$48K
- Corcept Therapeutics$25K
- Bayer$6K
- Mannkind Corporation$4K
- Ascensia Diabetes Care US Inc.$2K
- plus $7K from 34 others
Across 2,313 payments — averaging $151.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$351K
What the payments were for
- Consulting fees$17,17910%
- Speaking & faculty fees$106,69164%
- Travel & lodging$21,64813%
- Food & beverage$19,27412%
- Education$6620%
- Gifts$590%
- Other$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 138 | $74,155 |
| Dexcom, Inc. | 133 | $47,971 |
| Corcept Therapeutics | 96 | $24,723 |
| Bayer | 53 | $5,676 |
| Mannkind Corporation | 38 | $4,203 |
| Ascensia Diabetes Care US Inc. | 8 | $1,575 |
| Xeris Pharmaceuticals, Inc. | 49 | $1,147 |
| Amgen(2 entities) | 49 | $942 |
| Boehringer Ingelheim | 42 | $899 |
| Lilly USA, LLC | 32 | $624 |
| Abbott | 17 | $552 |
| AstraZeneca | 18 | $383 |
| Regeneron Healthcare Solutions, Inc. | 14 | $356 |
| AbbVie | 10 | $245 |
| Pfizer | 9 | $211 |
| BETA Bionics, Inc. | 6 | $195 |
| Tandem Diabetes Care, Inc. | 7 | $175 |
| Radius Health, Inc. | 6 | $159 |
| Sanofi-aventis U.S. LLC | 7 | $150 |
| Merck | 6 | $146 |
| Medtronic | 6 | $140 |
| Irhythm Technologies, Inc. | 5 | $135 |
| Sanofi | 1 | $125 |
| Novartis | 4 | $93 |
| Esperion Therapeutics, Inc. | 2 | $70 |
| Kyowa Kirin, Inc. | 3 | $65 |
| Insulet Corporation | 3 | $64 |
| Sequel Med Tech, LLC | 1 | $44 |
| Amarin Pharma, Inc. | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Recordati_rare_diseases_inc. | 1 | $35 |
| Madrigal Pharmaceuticals | 1 | $34 |
| Stryker | 1 | $33 |
| Zealand Pharma US, Inc. | 1 | $31 |
| GSK | 1 | $26 |
| Lexicon Pharmaceuticals, Inc. | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Arbor Pharmaceuticals, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Exact Sciences | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$41,908
- RYBELSUS$31,821
- Korlym$22,564
- DEXCOM STELO GLUCOSE BIOSENSOR$21,636
- Ozempic$19,452
- Kerendia$4,521
- AFREZZA$3,375
- DUPIXENT$250
- FREESTYLE LIBRE 3$138
- RECORLEV$135
- JARDIANCE$125
How this compares
$165,568 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 13 | $688,741 |
| OzempicSemaglutide | 429 | $500,154 |
| RybelsusSemaglutide | 187 | $228,204 |
| JardianceEmpagliflozin | 193 | $197,788 |
| FarxigaDapagliflozin Propanediol | 138 | $140,014 |
| Tresiba Flextouch U-200Insulin Degludec | 92 | $118,070 |
| KerendiaFinerenone | 101 | $116,513 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 130 | $114,645 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 107 | $95,725 |
| TrulicityDulaglutide | 52 | $60,941 |
| XareltoRivaroxaban | 37 | $59,592 |
| MounjaroTirzepatide | 55 | $58,296 |
| EntrestoSacubitril/Valsartan | 53 | $48,107 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 37 | $45,814 |
| AfrezzaInsulin Regular, Human | 27 | $44,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $74,155 | $728,358616 claims |
| Corcept TherapeuticsKorlym | $24,723 | $688,74113 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $899 | $293,512300 claims |
| AstraZenecaFarxiga | $383 | $140,014138 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $624 | $119,237107 claims |
| BayerKerendia | $5,676 | $116,513101 claims |
| AbbVieLinzess, Namzaric | $245 | $60,89461 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $26 | $51,27572 claims |
| NovartisEntresto | $93 | $48,10753 claims |
| Mannkind CorporationAfrezza | $4,203 | $44,78527 claims |
| PfizerEliquis | $211 | $36,06533 claims |
| MerckBelsomra | $146 | $10,94424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.
Other medical in Lancaster
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Linda RankLadera Ranch$105K
- Cheryl KyinnSan Diego$103K
- Kenny Davis TrinidadLos Angeles$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.